Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.54 |
| ▸ | DRD2 | P14416 | 6/20 | 0.54 |
| ▸ | DRD3 | P35462 | 6/20 | 0.54 |
| ▸ | HRH1 | P35367 | 5/20 | 0.54 |
| ▸ | HTR2A | P28223 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.54 |
| ▸ | HTR2C | P28335 | 4/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.54 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7810899 | 0.86 | KMT2A (0.53) | SLC6A4DRD2DRD3HRH1HTR2A | |
| Imipramine SCHEMBL4283852 | 0.79 | SLC6A4 (0.71) | SLC6A4DRD2DRD3HRH1HTR2A | |
| SCHEMBL7604567 | 0.78 | SLC6A4 (0.58) | SLC6A4DRD2DRD3HRH1HTR2A | |
| Hydrochloric Acid SCHEMBL7806943 | 0.77 | LMNA (0.59) | SLC6A4DRD2DRD3HRH1HTR2A | |
| SCHEMBL26967791 | 0.76 | SLC6A4 (0.69) | SLC6A4DRD2DRD3HRH1HTR2A | |
| Imipramine SCHEMBL20644144 | 0.76 | SLC6A4 (0.83) | SLC6A4DRD2DRD3HRH1HTR2A | |
| SCHEMBL5498800 | 0.74 | DRD2 (0.59) | DRD2DRD3CHRM1CHRM3ADRA1A | |
| SCHEMBL6965133 | 0.74 | DRD2 (0.62) | DRD2DRD3CHRM1CHRM3ADRA1A | |
| SCHEMBL4733904 | 0.73 | SLC6A4 (0.65) | SLC6A4DRD2DRD3HRH1HTR2A | |
| Hydrochloric Acid SCHEMBL7168274 | 0.73 | DRD2 (0.58) | DRD2DRD3CHRM1CHRM3ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | claimed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| EP-0820443-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING DIABETES | NOVO NORDISK AS (DK) | 2001-09-19 | — | — | EP | claimed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | claimed |
| EP-0820443-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-01-28 | — | — | EP | claimed |
| WO-1996031481-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | claimed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | disclosed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| EP-0820443-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING DIABETES | NOVO NORDISK AS (DK) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
| EP-0820443-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996031481-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | VEGFA, KDR, FLT4 | SLC6A4 2949/4885DRD2 2668/4885DRD3 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.